LateTIME: A Phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction

Jay H. Traverse, Timothy D. Henry, Douglas E. Vaughan, Stephen G. Ellis, Carl J. Pepine, James T. Willerson, David X.M. Zhao, Lara M. Simpson, Marc S. Penn, Barry J. Byrne, Emerson C. Perin, Adrian P. Gee, Antonis K. Hatzopoulos, David H. Mckenna, John R. Forder, Doris A. Taylor, Christopher R. Cogle, Sarah Baraniuk, Rachel E. Olson, Beth C. JorgensonShelly L. Sayre, Rachel W. Vojvodic, David J. Gordon, Sonia I. Skarlatos, Lemuel A. Moyé, Robert D. Simari

Research output: Contribution to journal › Article › peer-review

48 Scopus citations

Fingerprint

Dive into the research topics of 'LateTIME: A Phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction'. Together they form a unique fingerprint.

Medicine & Life Sciences